Download PDF
CC BY 4.0 · TH Open 2022; 06(02): e99-e106
DOI: 10.1055/a-1783-9744
Original Article

Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study

Elisa Grifoni 
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Andrea Baroncelli
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Gabriele Pinto
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Eleonora Cosentino
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Irene Micheletti
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Ira Signorini
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
,
Grazia Panigada
2   Internal Medicine, SS. Cosma and Damiano Hospital, Azienda USL Toscana Centro, Pescia, Italy
,
Giancarlo Landini
3   Internal Medicine, S. Maria Nuova Hospital, Azienda USL Toscana Centro, Florence, Italy
,
Luca Masotti
1   Internal Medicine II, S. Giuseppe Hospital, Azienda USL Toscana Centro, Empoli, Italy
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Few data exist on the use of edoxaban in cancer-associated venous thromboembolism (VTE) outside of clinical trials. Aim of this study was to evaluate the characteristics and outcomes of these patients in a real world clinical setting.

Methods We retrospectively analyzed the characteristics of patients with cancer-associated VTE who were prescribed edoxaban. Follow-up at 3, 6, and 12 months was performed: VTE recurrences, bleedings, mortality, cancer progression and treatment, edoxaban interruption and its reason were assessed.

Results Fifty-four patients, 38 females (70.4%), mean age 71 ± 14 years, were enrolled. In 38 patients (70.4%), the episode of VTE was the first one, in 28 (51.8%) it was an isolated deep vein thrombosis (DVT), in 13 (24.1%) a pulmonary embolism (PE) associated with DVT, in 13 (24.1%) an isolated PE. Median time between cancer and VTE diagnosis was 6 (interquartile range [IQR] 2–47) months. Median time between VTE diagnosis and edoxaban prescription was 36 (IQR 7–117) days. At 3, 6, and 12 months the incidence of all-cause mortality was 16.6, 22.2, and 38.8%, that of VTE recurrence 1.8, 1.8, and 3.7%, and that of major bleeding 7.4, 9.2, and 12.9%, respectively. No bleeding was fatal. Of the 33 patients alive at 12 months, 32 (96.9%) were still on edoxaban therapy, in seven (21.2%) cancer was in progression.

Conclusion Our study, conducted on a real world population of patients with cancer-associated VTE, confirms the results of randomized controlled clinical trials, and supports the use of edoxaban as effective and safe treatment in this context.

Keywords

cancer - venous thromboembolism - bleeding - edoxaban - low molecular weight heparin

Supplementary Material



Publication History

Received: 30 November 2021

Accepted: 01 February 2022

Accepted Manuscript online:
01 March 2022

Article published online:
17 May 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Wharin C, Tagalakis V. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev 2014; 28 (01) 1-8
    CrossrefPubMedSearch in Google Scholar
  • 2 Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147 (02) 475-483
    CrossrefPubMedSearch in Google Scholar
  • 3 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedSearch in Google Scholar
  • 4 Kraaijpoel N, Di Nisio M, Mulder FI. et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost 2018; 118 (08) 1439-1449
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedSearch in Google Scholar
  • 6 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
    CrossrefPubMedSearch in Google Scholar
  • 7 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedSearch in Google Scholar
  • 8 Khorana AA, Noble S, Lee AYY. et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (09) 1891-1894
    CrossrefPubMedSearch in Google Scholar
  • 9 Prisco D, Tufano A, Cenci C. et al. Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 2019; 14 (01) 21-38
    CrossrefPubMedSearch in Google Scholar
  • 10 Streiff MB, Holmstrom B, Angelini D. et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw 2018; 16 (11) 1289-1303
    CrossrefPubMedSearch in Google Scholar
  • 11 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
    CrossrefPubMedSearch in Google Scholar
  • 12 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38 (05) 496-520
    CrossrefPubMedSearch in Google Scholar
  • 13 Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol 2019; 30 (06) 897-907
    CrossrefPubMedSearch in Google Scholar
  • 14 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedSearch in Google Scholar
  • 15 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedSearch in Google Scholar
  • 16 Søgaard M, Nielsen PB, Skjøth F, Kjaeldgaard JN, Larsen TB. Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: a nationwide cohort study. Cancer Med 2019; 8 (03) 1044-1053
    CrossrefPubMedSearch in Google Scholar
  • 17 Kohn CG, Lyman GH, Beyer-Westendorf J. et al. Effectiveness and safety of rivaroxaban in patients with cancer-associated venous thrombosis. J Natl Compr Canc Netw 2018; 16 (05) 491-497
    CrossrefPubMedSearch in Google Scholar
  • 18 Soff GA, Mones J, Wilkins C. et al. Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Res Pract Thromb Haemost 2019; 3 (03) 349-356
    CrossrefPubMedSearch in Google Scholar
  • 19 Di Nisio M, van Es N, Carrier M. et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost 2019; 17 (11) 1866-1874
    CrossrefPubMedSearch in Google Scholar
  • 20 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Mulder FI, van Es N, Kraaijpoel N. et al. Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13-19]. Thromb Res 2020; 191: 156-159
    CrossrefPubMedSearch in Google Scholar
  • 22 Bosch FTM, Mulder FI, Huisman MV. et al. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost 2021; 19 (12) 3008-3017
    CrossrefPubMedSearch in Google Scholar
  • 23 Agnelli G, Muñoz A, Franco L. et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost 2021; (e-pub ahead of print)
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 Steffel J, Verhamme P, Potpara TS. et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
    CrossrefPubMedSearch in Google Scholar
  • 25 Kim S-A, Yhim H-Y, Bang S-M. Current management of cancer-associated venous thromboembolism: focus on direct oral anticoagulants. J Korean Med Sci 2019; 34 (06) e52
    CrossrefPubMedSearch in Google Scholar